Of the 3 patients receiving 0.25 mg/kg TAK-164, 1 experienced grade 3 nausea, grade 4 platelet count decrease, and grade 4 neutrophil count decrease, whilst another patient experienced grade 4 platelet count decrease and grade 4 hepatic failure (with elevations of ALT and AST from day 8 of cycle 1 with levels continuing to increase through to day 9 of cycle 2; and elevated bilirubin and alkaline phosphatase detected on day 8 of cycle 2). Here, GPT is linked to liver failure.